Wedbush Estimates argenx's Q2 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX - Free Report) - Wedbush upped their Q2 2025 earnings per share (EPS) estimates for argenx in a research report issued on Friday, December 27th. Wedbush analyst D. Nierengarten now expects that the company will earn $2.26 per share for the quarter, up from their previous forecast of $2.23. Wedbush currently has a "Outperform" rating and a $655.00 target price on the stock. The consensus estimate for argenx's current full-year earnings is $2.20 per share. Wedbush also issued estimates for argenx's Q3 2025 earnings at $2.70 EPS, Q4 2025 earnings at $3.07 EPS and FY2025 earnings at $9.94 EPS.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. During the same quarter in the prior year, the company earned ($1.25) earnings per share.

ARGX has been the topic of a number of other research reports. Truist Financial upped their target price on argenx from $540.00 to $660.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Citigroup upped their price objective on shares of argenx from $512.00 to $635.00 and gave the company a "buy" rating in a research note on Thursday, October 17th. Evercore ISI lifted their target price on shares of argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a research note on Thursday, November 21st. HC Wainwright reaffirmed a "buy" rating and issued a $617.00 price target on shares of argenx in a research note on Wednesday, November 20th. Finally, Piper Sandler increased their price objective on argenx from $553.00 to $620.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $639.78.

argenx Price Performance

argenx stock traded down $6.35 during mid-day trading on Monday, hitting $619.96. The company's stock had a trading volume of 119,145 shares, compared to its average volume of 305,003. argenx has a 52-week low of $349.86 and a 52-week high of $644.97. The company has a market cap of $37.43 billion, a PE ratio of -704.50 and a beta of 0.59. The firm's 50 day moving average is $599.42 and its 200 day moving average is $533.19.

Institutional Investors Weigh In On argenx

A number of hedge funds have recently bought and sold shares of the company. Point72 Hong Kong Ltd bought a new stake in shares of argenx in the second quarter valued at approximately $76,000. Cromwell Holdings LLC raised its stake in argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock valued at $85,000 after purchasing an additional 66 shares during the last quarter. GAMMA Investing LLC boosted its holdings in argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company's stock valued at $94,000 after purchasing an additional 56 shares during the period. Blue Trust Inc. grew its position in argenx by 413.9% in the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company's stock worth $201,000 after purchasing an additional 298 shares during the last quarter. Finally, Gallacher Capital Management LLC bought a new position in shares of argenx during the 2nd quarter worth about $202,000. 60.32% of the stock is currently owned by institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.